DDInter121 DDInter1435
Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of <i>Plasmodium spp.</i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Artemether {u} (Compound) treats {v} (Disease) malaria
Artemether {u} (Compound) binds {v} (Gene) CYP2D6
Artemether {u} (Compound) upregulates {v} (Gene) HDGFRP3
Artemether {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Griseofulvin
Artemether {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fedratinib
Artemether {u} may lead to a major life threatening interaction when taken with {v} Troleandomycin
Artemether {u} may lead to a major life threatening interaction when taken with {v} Saquinavir
Artemether (Compound) treats malaria (Disease)
Artemether (Compound) binds CYP2D6 (Gene)
Artemether (Compound) upregulates HDGFRP3 (Gene)
Artemether may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin
Artemether may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Artemether may lead to a major life threatening interaction when taken with Troleandomycin
Artemether may lead to a major life threatening interaction when taken with Saquinavir